Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELDN Eledon Pharmaceuticals, Inc.

Trading 10-09 10:25:44 EDT

2.46

+0.04

+1.65%

High2.51	Low2.42	Vol133.64K
Open2.42	D1 Closing2.42	Amplitude3.51%
Mkt Cap199.90M	Tradable Cap183.44M	Total Shares81.26M
T/O329.14K	T/O Rate0.18%	Tradable Shares74.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELDN","market":"US","secType":"STK","nameCN":"Eledon Pharmaceuticals, Inc.","latestPrice":2.46,"timestamp":1791555926285,"preClose":2.42,"halted":0,"volume":133640,"delay":0,"changeRate":0.016528925619834725,"floatShares":74567100,"shares":81261200,"eps":-0.986689,"marketStatus":"Trading","change":0.04,"latestTime":"10-09 10:25:44 EDT","open":2.42,"high":2.505,"low":2.42,"amount":329141.15416,"amplitude":0.035124,"askPrice":2.47,"askSize":295,"bidPrice":2.46,"bidSize":546,"shortable":3,"etf":0,"ttmEps":-0.986689,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":2.42,"preHourTrading":{"tag":"盘前","latestPrice":2.48,"preClose":2.42,"latestTime":"09:20 EDT","volume":7642,"amount":18649.241054600003,"timestamp":1791552056328,"change":0.06,"changeRate":0.024793,"amplitude":0.053719},"postHourTrading":{"tag":"盘后","latestPrice":2.4256,"preClose":2.42,"latestTime":"19:30 EDT","volume":17629,"amount":42464.656,"timestamp":1791502203340,"change":0.0056,"changeRate":0.002314,"amplitude":0.010579},"volumeRatio":1.178827,"impliedVol":0.6963,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/ELDN/tweets","defaultTab":"tweets","newsList":[{"id":"2673249081","title":"Eledon to Present Phase 2 Bestow Kidney Transplant Trial Patient-Reported Outcomes for Tegoprubart at ASN Kidney Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673249081","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673249081?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:06","pubTimestamp":1791230819,"startTime":"0","endTime":"0","summary":"Eledon to present Phase 2 BESTOW kidney transplant trial patient-reported outcomes for tegoprubart at ASN Kidney Week 2026Eledon flagged new patient-reported outcomes from its Phase 2 BESTOW kidney-tr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL72QtG3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","IE00BKPKM429.USD","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014005.SGD","BK4585","BK4588","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014021.USD","NDAQ","LU2095319765.USD","IE00BN0W2W23.USD","BCDF","BK4139","ELDN","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","BK4112","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669990125","title":"Eledon Shares Rise on Fast-Track Designation for Kidney Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2669990125","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669990125?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:06","pubTimestamp":1790093160,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals shares rose after the company said its kidney treatment was granted fast-track designation by the Food and Drug Administration.The stock rose 13% to $3.04 on Tuesday. Shares are up 87% this year.Patients treated with tegoprubart in a Phase 2 trial had statistically significantly higher kidney function through 24 months compared with tacrolimus, Eledon said.The fast-track designation is to develop tegoprubart as a prevention for rejections in kidney transplants, Eledon said. No rejections occurred in the tegoprubart arm of the trial after six months post-transplant, it added.The FDA's designation is meant to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs.The biotechnology company said it is on track to initiate its Phase 3 trial of tegoprubart in kidney transplantation in the fourth quarter of this year. The trial is expected to enroll about 600 patients, it said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669757123","title":"Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669757123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669757123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:20","pubTimestamp":1790090418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eledon Pharmaceuticals (ELDN), Viking Therapeutics (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-viking-therapeutics-vktx-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-viking-therapeutics-vktx-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","IE0009355771.USD","LU2468319806.SGD","IBBQ","BK4585","LU0122379950.USD","IE00B2B36J28.USD","BK4588","LABU","LU0128526141.USD","BK4533","BK4139","HCSG","BK4534","LU1057294990.SGD","LU2089984988.USD","LU0029874061.USD","IE00BJJMRZ35.SGD","TBXU","BIB","LU0320765992.SGD","LU0058720904.USD","LU0889565916.HKD","BBH","IBB","XLV","IE00BFTCPJ56.SGD","OZEM","XBI","THNR","BK4137","IE0002141913.USD","VKTX","ELDN","LU1571399168.USD","IE00B4R5TH58.HKD","LU1061106388.HKD","LU2242646821.SGD","LU0109394709.USD","LU0289739699.SGD","LU0868494617.USD","LU1983299246.USD","LU2242652126.USD","PJP","BK4599","SG9999001440.SGD","IE00BJT1NW94.SGD","AMGN","LU2112291526.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146980","title":"Eledon Reports 24-Month Phase 2 Bestow Extension Data Showing Higher eGFR with Tegoprubart vs Tacrolimus in Kidney Transplant Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146980","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146980?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:02","pubTimestamp":1790074963,"startTime":"0","endTime":"0","summary":"Eledon reports 24-month Phase 2 BESTOW extension data showing higher eGFR with tegoprubart vs tacrolimus in kidney transplant patientsEledon disclosed updated long-term Phase 2 BESTOW extension result","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL93bjZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","SG9999014005.SGD","NDAQ","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","ELDN","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","LU2210150020.SGD","BK4585","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014039.USD","BK4588","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146514","title":"Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results at the International Congress of the Transplantation Society","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146514?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:00","pubTimestamp":1790074803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA3SNS3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666138529","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666138529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666138529?lang=en_us&edition=fundamental","pubTime":"2026-09-11 19:14","pubTimestamp":1789125285,"startTime":"0","endTime":"0","summary":"Alliance Entertainment  shares were up more than 46% in Friday's premarket activity following the company's fiscal 2026 results.ACV Auctions  stock was nearly 44% higher after the company agreed to be acquired by Copart .Frequency Electronics  shares were up more than 31% after the company reported its fiscal Q1 results.RH  stock was 9% higher following the company's fiscal Q2 results.Eledon Pharmaceuticals  shares were up 6% following a 1.4% loss in the prior session.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0097036916.USD","BK4157","BK4159","LU0823421333.USD","LU0353189680.USD","LU2041044095.USD","BK4137","BK4139","IE0008368304.USD","LU2092937221.SGD","LU0823421416.USD","ELDN","LU0323239441.USD","CPRT","ACVA","LU2087625088.SGD","LU2360108059.USD","AENT","FEIM","RH","LU0323240290.USD","BK4588","BK4178","BK4585","BK4559","LU2298321311.HKD","LU0353189763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666542587","title":"Eledon to Present Long-Term Tegoprubart Data at Transplantation Society Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666542587","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666542587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:05","pubTimestamp":1788951927,"startTime":"0","endTime":"0","summary":"Eledon to Present Long-Term Tegoprubart Data at Transplantation Society CongressEledon will present Phase 2 BESTOW and BESTOW EXTENSION data on tegoprubart in kidney transplant rejection at TTS Congre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL1JFrJM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014005.SGD","BCDF","IE00BQXX3F31.USD","LU0314104364.USD","IE00BN0W2V16.EUR","ELDN","BK4585","BK4139","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","IE00BQXX3C00.GBP","SG9999014039.USD","LU2210150020.SGD","LU2210149790.SGD","SG9999014021.USD","BK4112","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664803903","title":"Analysts’ Top Healthcare Picks: Align Tech (ALGN), Eledon Pharmaceuticals (ELDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664803903","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664803903?lang=en_us&edition=fundamental","pubTime":"2026-09-03 23:50","pubTimestamp":1788450609,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Align Tech (ALGN) and Eledon Pharmaceuticals (ELDN) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-align-tech-algn-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-align-tech-algn-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LU1917777945.USD","LABU","HCSG","ELDN","BK4585","BK4139","ALGN","LU2023250843.SGD","BK4137","LU2106854487.HKD","BK4198","BK4504","BK4581","LU2023250504.SGD","XBI","BK4534","BK4588","GLAM","XLV","LU0029874061.USD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664287674","title":"Eledon Submits FDA IND for Tegoprubart Islet Cell Transplant Trial in Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2664287674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664287674?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:01","pubTimestamp":1788433311,"startTime":"0","endTime":"0","summary":"Eledon submits FDA IND for tegoprubart islet cell transplant trial in type 1 diabetesEledon submitted an IND to the FDA for a registrational tegoprubart trial in islet cell transplantation for type 1 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL7TSdzD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BQXX3D17.EUR","SG9999014021.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","BCDF","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","ELDN","IE00BQXX3F31.USD","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","BK4588","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664762148","title":"Eledon Pharmaceuticals Announces Islet Cell Transplantation Ind Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664762148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664762148?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:00","pubTimestamp":1788433201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA6KS1HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659314152","title":"Clene Q2 Net Loss Widens on Higher Other Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659314152","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659314152?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711241,"startTime":"0","endTime":"0","summary":"Clene Q2 net loss widens on higher other expensesOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr, driven by higher other expensesCompany closed $7 mln stock offering and extended debt ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0FV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","AEON","CLNN","ELDN","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659606371","title":"Eledon Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659606371","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659606371?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:48","pubTimestamp":1786654082,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryEledon Pharmaceuticals IncELDN.OQreported a quarterly adjusted loss of 27 cents per share for the quarter end","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A273:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167493","title":"Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167493","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167493?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:30","pubTimestamp":1786653025,"startTime":"0","endTime":"0","summary":"Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61194562/eledon-pharma-q2-eps-0-27-misses-0-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162006","title":"Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162006","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162006?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652214,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Q2 net loss widens on warrant liability changesOverviewUS biotech reported Q2 net loss widened yr/yr, driven by non-cash warrant liability changesOperating expenses for Q2 fell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A158:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHV","BK4139","UNCY","PROK","ELDN","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659116212","title":"Eledon Q2 FY26 Net Loss Widens to $31.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659116212","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659116212?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:08","pubTimestamp":1786651708,"startTime":"0","endTime":"0","summary":"Eledon Q2 FY26 net loss widens to $31.6 millionEledon Pharmaceuticals posted a wider Q2 2026 net loss of USD 31.6 million, or USD 0.27 per share, versus USD 11.2 million.R&D expense fell to USD 18.2 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL8zfMQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","ELDN","IE00BN0W2V16.EUR","NDAQ","BCDF","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK4585","BK4139","SG9999014021.USD","LU2095319765.USD","SG9999014013.SGD","IE00BN0W2W23.USD","LU0314104364.USD","LU2210149790.SGD","BK4112","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014039.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659625591","title":"Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659625591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659625591?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUABV2VCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659558162","title":"Eledon Pharmaceuticals Q2 Operating Expenses USD 22.869 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659558162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659558162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX3N8327:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933463","title":"Eledon Pharmaceuticals Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933463","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933463?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:36","pubTimestamp":1786361770,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc <ELDN.OQ> expected to post a loss of16cents a share - Earnings PreviewEledon Pharmaceuticals IncELDN.OQELDN.Ois expected to  show no change in quarterly revenue when it repo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4470NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655369246","title":"NewcelX Prices USD 1.4 Million Private Placement at USD 4.03 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2655369246","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655369246?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:00","pubTimestamp":1785502836,"startTime":"0","endTime":"0","summary":"NewcelX prices USD 1.4 million private placement at USD 4.03 per shareNewcelX priced a USD 1.4 million private placement at USD 4.03 per share, a 20% premium to the July 30 close.Deal covers 347,134 c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL9Dppng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","BK4139","BK4112","BCDF","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","BK4585","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","ELDN","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","NCEL","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654051589","title":"Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2654051589","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654051589?lang=en_us&edition=fundamental","pubTime":"2026-07-25 20:14","pubTimestamp":1784981685,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/news/heres-why-were-watching-eledon-pharmaceuticals-nasdaqeldn-ca-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/news/heres-why-were-watching-eledon-pharmaceuticals-nasdaqeldn-ca-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NQmain","QID","QQQY","QQQ","NVIW.SI","MNQmain","TECS","IYW","QDTE","NDX","QQQA","QLD","BK4139","ELDN","SQQQ","TQQY","QQQM","GPIQ","PSQ","QQQJ","FTEC","QYLG",".IXIC","ONEQ","TQQQ","JEPQ","QQQE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eledon.com","stockEarnings":[{"period":"1week","weight":-0.0062},{"period":"1month","weight":-0.1741},{"period":"3month","weight":-0.3714},{"period":"6month","weight":-0.2194},{"period":"1year","weight":-0.1568},{"period":"ytd","weight":0.6026}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.139},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.166113},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.000872},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.044379},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009056},{"month":5,"riseRate":0.583333,"avgChangeRate":0.748048},{"month":6,"riseRate":0.25,"avgChangeRate":-0.164848},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.086359},{"month":8,"riseRate":0.25,"avgChangeRate":-0.042182},{"month":9,"riseRate":0.25,"avgChangeRate":0.065821},{"month":10,"riseRate":0.461538,"avgChangeRate":2.086221},{"month":11,"riseRate":0.5,"avgChangeRate":-0.069266},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.094259}],"exchange":"NASDAQ","name":"Eledon Pharmaceuticals, Inc.","nameEN":"Eledon Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eledon Pharmaceuticals, Inc.,ELDN,Eledon Pharmaceuticals, Inc.股票,Eledon Pharmaceuticals, Inc.股票老虎,Eledon Pharmaceuticals, Inc.股票老虎国际,Eledon Pharmaceuticals, Inc.行情,Eledon Pharmaceuticals, Inc.股票行情,Eledon Pharmaceuticals, Inc.股价,Eledon Pharmaceuticals, Inc.股市,Eledon Pharmaceuticals, Inc.股票价格,Eledon Pharmaceuticals, Inc.股票交易,Eledon Pharmaceuticals, Inc.股票购买,Eledon Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction